This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chadwick, D. Articles by Marson, T. Search for Related Content Social Bookmarking                         What's this?

Review: Comparing drug treatments in epilepsy

University of Liverpool, Liverpool, UK, D.W.Chadwick{at}liverpool.ac.uk

Arif Shukralla

University of Liverpool, Liverpool, UK

Tony Marson

University of Liverpool, Liverpool, UK

The great majority of randomised controlled trials (RCTs) that compare antiepileptic drugs are industry sponsored and have the objective of obtaining a monotherapy license for a drug. Such trials do not inform everyday clinical practice as they tend to be too short and to depart from clinical practice by restricting clinicians in their choice of actions. The data that exists provides evidence that drugs with actions on voltage-gated sodium channels provide best seizure control for localised onset seizures and epilepsy syndromes, while valproate provides best seizure control for generalised epilepsy and unclassified syndromes. Drugs do, however, vary in their tolerability over the short term and in their risk for rare serious idiosyncratic adverse events, chronic toxicity and teratogenicity; issues that cannot be examined within the scope of RCTs.

Key Words: epilepsy • antiepileptic drugs • partial epilepsies • idiopathic generalised epilepsy • risk/benefit

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 3, 181-187 (2009)
DOI: 10.1177/1756285609102327


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?